Department of Surgical Oncology, Montpellier Cancer Institute (Institut du Cancer de Montpellier) (ICM), Montpellier, France.
Department of Surgical Oncology, Montpellier Cancer Institute (Institut du Cancer de Montpellier) (ICM), Montpellier, France.
Crit Rev Oncol Hematol. 2024 Oct;202:104469. doi: 10.1016/j.critrevonc.2024.104469. Epub 2024 Aug 5.
Ovarian carcinoma remains the most lethal gynaecologic malignancy. Half of all high-grade serous ovarian cancers (HGSOCs) have a homologous recombination deficiency (HRD) with regard to the repair of double-strand DNA breaks and are candidate to receive maintenance treatment with PARP inhibitors. While a wealth of literature exists regarding the therapeutic guidance of patients from a medical standpoint, the influence of the HRD status on the surgical outlook has been comparatively limited. In this review, the clinical and biological features of advanced ovarian cancers with BRCA1/2 mutation and/or HRD status are considered with particular reference to their impact on the surgical management and on the medico-surgical sequence. The modification of the surgical indications according to the results of molecular testing in first-line and recurrent settings are discussed.
卵巢癌仍然是最致命的妇科恶性肿瘤。大约一半的高级别浆液性卵巢癌（HGSOC）存在同源重组缺陷（HRD），导致双链 DNA 断裂的修复能力受损，这些患者是接受 PARP 抑制剂维持治疗的候选人群。尽管从医学角度来看，有大量关于患者治疗指导的文献，但 HRD 状态对手术预后的影响相对有限。在这篇综述中，考虑了具有 BRCA1/2 突变和/或 HRD 状态的晚期卵巢癌的临床和生物学特征，特别关注它们对手术管理以及医疗-手术顺序的影响。讨论了根据一线和复发性治疗中分子检测结果修改手术适应证的问题。
